COMP <GO>
JNJ vs ABBV // FORWARD P/E MULTIPLE
Johnson & Johnson (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: JNJ 8
— ABBV 7
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JNJ VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JNJ | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.90% | 70.20% | -2.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.50% | 29.00% | -3.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 33.3x | -14.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.97% | 3.47% | -0.50 | ABBV | /fcf-yield <GO> |
| Operating Margin | 34.70% | 24.60% | +10.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 28.50% | 6.90% | +21.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.00% | 8.60% | -2.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.59 | 5.33 | +0.26 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 72.8 | -12.43 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 23.0x | 113.1x | -90.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.49B | $513.86B | $148.63B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JNJ REV | ABBV REV | JNJ GROSS % | ABBV GROSS % | JNJ FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $94.19B | $61.16B | 67.9% | 70.2% | $19.70B | $17.82B |
| FY 2024 | $88.82B | $56.33B | 69.1% | 70.0% | $19.84B | $17.83B |
| FY 2023 | $85.16B | $54.32B | 44.0% | 44.0% | $18.96B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JNJ // BETA 1.08
ABBV // BETA 1.15